Your Best Partner for Glyco-engineered Cell Construction Based on O-Man Pathway

With the help of the Glycan Display Platform, we provide various Glyco-engineered Cell Construction services such as O-GalNAc Pathway, O-Fuc Pathway, C-Man Pathway and O-Glc Pathway-based Glyco-engineered Cell Construction. The biosynthesis of O-mannose-initiating glycans begins at the cytoplasmic surface of the endoplasmic reticulum (ER). It is initiated by the protein O-mannosyltransferase 1 (POMT1) and the protein O-mannosyltransferase 2 (POMT2) enzyme complex. CD BioGlyco elaborates O-Man with the help of precise gene editing services to form highly complex and specific structures. We construct specific cell lines to lay the foundation for further high-throughput screening and analysis.

Fig.1 Four classifications of core O-mannose structures. (Sheikh, et al., 2017)

• Gene targeting service

At CD BioGlyco, we use clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) in the human embryonic kidney 293 (HEK293) cells, combined with sensitive and quantitative O-Man glycoproteomics, to identify in detail the homologous family of protein glycosyltransferases encoded by various genes. The O-Man pathway is relatively confined to specific proteins or proteins: the two types of O-Man glycosylations primarily serve the α-dystroglycan (α-DG) or the cadherin superfamily.

• We catalyze the enzyme expression of the α-DG structurally complex and diverse O-Man glycans by regulating two human POMT1 and POMT2 genes.
• We provide O-Man pathway regulatory services coordinated by four orthologous TMTC1-4 genes.
• With the help of knockout, we provide HEK293 cell construction services without functional TMTC genes.
• We offer the following analytical services: enzyme digestion services, liquid chromatography analysis, sequence analysis, and liquid chromatography-tandem mass spectrometry (LC-MS) analysis. Our researchers quantify the relative changes in O-Man glycosylation between cells. In addition, we reveal POMT1-2 and TMTC1-4 family-targeted O-Man by quantitative O-Man glycoproteomics.

Fig.2 O-Man glycosylation pathway maps with glycosyltransferase genes. (CD BioGlyco)

Publication

Applications of O-Man Pathway-based Glyco-engineered Cells

• O-Man pathway-based glyco-engineered cells play a key role in multiple human diseases research, e.g. congenital muscular dystrophy (CMD), cancer metastasis, and viral entry.
• O-Man pathway-based glyco-engineered cell is a new target for the glycosylation studies of cell adhesion proteins.

CD BioGlyco is a specialized glycobiology company offering a diverse range of glycan displays to our clients. We have a knowledgeable operational team to help clients plan and complete projects. Moreover, we provide a Cell-based Glycan Display Array. Please feel free to contact us for details.